A small clinical trial published in JCO Oncology Advances reports that a supplement called oxaloacetate, a molecule already present in the human body, was associated with noticeable improvements in thinking, memory, concentration and fatigue among breast cancer survivors. The study was led by Dr. Patricia Ganz, a distinguished professor at UCLA, and its first author is Ganz herself.
The trial enrolled 18 women diagnosed with early-stage breast cancer one to five years earlier, all of whom reported substantial cognitive difficulties at the start. Most had received chemotherapy, and nearly 90% were still on endocrine therapy during the study. Each participant took 500 milligrams twice a day for eight weeks. Of the 18, 16 completed the full course, and every one of them reported significant improvement in cognitive symptoms. On the study's main measure of perceived cognitive impairment, the group average rose from 29.1 to 55.5, moving into the range the researchers considered normal rather than impaired. Signs of improvement appeared by week four.
Standardized tests also pointed in a positive direction, with gains in processing speed and executive function, the mental abilities used for planning, focus and organizing tasks. Participants reported less fatigue and better physical functioning. Side effects were mostly digestive, such as bloating, constipation, diarrhea and nausea, and two women stopped taking the supplement because of them. No serious adverse events were recorded.
The reasoning behind the study rests on the idea that inflammation tied to cancer and its treatments may disrupt glutamate signaling between nerve cells and the way brain cells produce and use energy. Oxaloacetate plays a role in both energy production and glutamate regulation, which made it a candidate worth testing. Cancer-related cognitive impairment affects an estimated 15% to 25% of breast cancer survivors, and the researchers note that treatment options for it remain few.
The researchers themselves stress that the findings are preliminary. The trial was small and had no placebo or comparison group, so it cannot show whether oxaloacetate itself produced the improvements. The team is preparing a randomized, placebo-controlled phase II trial, expected to begin enrolling in late 2026, and is running mouse studies to understand how the molecule works. The research received partial funding from the Breast Cancer Research Foundation and the National Cancer Institute.